Tech Company Financing Transactions
On Target Laboratories Funding Round
Johnson & Johnson Development Corporation and private investors participated in a $44 million Series B capital raise for On Target Laboratories. The round was announced on 3/15/2018.
Transaction Overview
Company Name
Announced On
3/15/2018
Transaction Type
Venture Equity
Amount
$44,000,000
Round
Series B
Investors
Johnson & Johnson Development Corporation (Lead Investor)
Proceeds Purpose
The funding will be used to fully develop the company's lead molecule, OTL38, in ovarian and lung cancers as well as introduce an additional molecule into the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1281 Win Hentschel Blvd.
Lafayette, IN 47906
USA
Lafayette, IN 47906
USA
Phone
Website
Email Address
Overview
The focus of On Target Laboratories is the discovery and development of small molecules that, when conjugated with fluorescent dyes, target and illuminate specific cancerous cells and other diseased tissue.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chris Barys
Chief Operating Officer
Timothy Biro
Chief Scientific Officer
Philip Low
VP - Finance
Kathleen Ward
VP - Marketing
Benjamin Lundgren
VP - R & D
Sumith Kularatne
VP - Regulatory Affairs
Kim Fabrizio
Browse more venture capital transactions:
Prev: 3/15/2018: Solebit venture capital transaction
Next: 3/16/2018: Kiddom venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. All VC database entries reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs